Hit enter to search or ESC to close
Absolute Markets Insights has announced the addition of new informative data titled as, Dengue Drugs Market to its extensive repository. The aim of this report is to enable the readers to focus on some significant aspects of the businesses such as, recent developments, technological platforms, various standard operating procedures, and tools, which helps to boost the performance of the industries. Primary and secondary research techniques have been used to examine the desired data effectively.
Different financial facts and figures have been elaborated by using effective graphical presentation techniques such as, graphs, charts, diagrams and tables which helps to understand the complex things clearly to the readers. Additionally, it offers various internal and external attributes which are driving or restraining the flow of the businesses. This comprehensive analysis ponders the approaches to discover the global opportunities to get customers rapidly, which helps to develop the businesses.
Global Dengue Drugs Market is expected to grow at a CAGR of +2.6% from 2022 to 2030
Click to view the full report: https://www.absolutemarketsinsights.com/reports/Dengue-Drugs-Market-617
Top Key Players includes: AbbVie Inc., ABIVAX, GSK group of companies, Johnson & Johnson Services, Inc., Micro Labs Ltd., Pfizer Inc., Sanofi, Sun Pharma and Takeda Pharmaceutical Company Limited
The reported cases of dengue to World Health Organization in 2019 were 4.2 million and are spreading to multiple countries. This high number of patients has triggered numerous research and development activities for developing effective and economical dengue drugs. For instance, Indian Ministry of Science and Technology in partnership with Sun Pharmaceutical Industries Ltd. developed an herbal medicine for dengue in 2019. Similarly, 60 Degrees Pharmaceuticals of Singapore was granted a patent for a novel dengue drug named Celgosivir in 2014. These on-going developments of newer drugs are anticipated to drive the global dengue drugs market in forecast years. The maximum potential market for dengue drugs is US $338 million per year. Over 2-3 billion of the world’s population is at risk of contracting dengue. Approximately 3–6% of clinical cases progress from an acute but uncomplicated febrile form of the disease to dengue hemorrhagic fever or dengue shock syndrome. This manifestation is reported to be fatal in nature. Drugs are a intervention that may be useful for patients who contract dengue because they did not receive an approved dengue vaccine or for whom prior vaccination was ineffective.
Global Dengue Drugs Market: Report Scope
By Distribution Channel
By Drug Class
By Route of Administration
Key Benefits for Industry Participants & Stakeholders:
Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: [email protected]
Phone: IN +91-7400-24-24-24, US +1-510-420-1213
About the author
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.